Ac immune reports full year 2023 financial results and provides a corporate update

Ac immune reports full year 2023 financial results and provides a corporate update aci-24.060 abate phase 2 trial to report abeta-pet imaging results in q2 and h2 aci-7104.056 vacsyn phase 2 trial in parkinson's disease on track for interim data in h2 aci-24.060 for alzheimer's disease (ad) received fda fast track designation aci-35.030 retain phase 2b program in preclinical (pre-symptomatic) ad patients, initiated by collaboration partner cash of chf 103 million at year end, plus the chf 15 million milestone payment received on february 1, 2024 and the next chf 25 million aci-35.030-related milestone, provides funding into 2026 lausanne, switzerland, march 14, 2024 – ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the year ended december 31, 2023, and provided a corporate update. dr. andrea pfeifer, ceo of ac immune sa, commented: “we made significant progress in 2023 advancing our three innovative active immunotherapy programs in phase 2 clinical trials in alzheimer's and parkinson's diseases.
ACIU Ratings Summary
ACIU Quant Ranking